Figshareopen access
Table 1_Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis.docx
pharmacology, camzyos, cardiac myosin inhibitor, disproportionality analysis, faers, mavacamten, obstructive hypertrophic cardiomyopathy, pharmacovigilance
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 669803
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.